Gastric cancer with low PD-L1 expression may not benefit from immunotherapy!
For the treatment of neutropenic septic shock, β-lactam combined with amikacin may be the best solution | Frontier Express
Express reduced the bleeding rate by 85%, and the long-term effect of the phase 3 clinical trial of hemophilia gene therapy was positive
The first batch of express in 2022, FDA today approves innovative insomnia therapy
Express aims to functionally cure hepatitis B, and the first dose of a new immunotherapy phase 2 trial has been completed
Express focuses on AI and difficult-to-drug targets, AstraZeneca reaches two R&D cooperation
Express the development of small molecules to target and degrade RNA!
Antisense RNA fine-tunes gene expression of the type II MazEF toxin-antitoxin system
Express Improves the Efficacy of Immune Checkpoint Inhibitors, Innovative Cancer Vaccine Enters Phase 2/3 Clinical Trials
Express significantly reduces the risk of recurrence after lung cancer surgery, and Keytruda is expected to benefit patients at an earlier stage
Express FDA approves AbbVie's JAK inhibitor for atopic dermatitis
Express uses red blood cells to extensively stimulate the immune system, and innovative anti-cancer therapy enters the clinic
Front Immunol: Antcin K inhibits the expression of TNF-α, IL-1, and IL-8 in synovial fibroblasts and improves cartilage degradation
KHYG-1 NK cells expressing CD38-specific chimeric antigen receptors in Myeloma New Horizons
2021 ASH deep ploughs MM, broad extension new disease, Isatuximab research progress express
[2021 ASH Express] Focus on the prognosis study of MPN patients and the whole management of MF patients
Effective mixed backbone antisense oligonucleotides inhibit the expression of mutant C9orf72
Express for the treatment of leukemia, the FDA granted the "ready-to-use" placental-derived NK cell therapy fast track qualification
Express significantly reduces the risk of disease onset, IL-17A inhibitors are approved for Category 5 indications
Express two styles in two days!